Meracle improves the management and outcomes of chronic respiratory conditions by increasing the efficiency of medication delivered into the lungs, while tracking intake data to augment the assessment of treatment outcomes. Chronic respiratory conditions, such as asthma, COPD and COVID-19 affects more than 600 million people globally. We seek to solve the challenges faced by 7 in 10 of these patients, who struggle with ineffective and inconsistent inhaled medication intake. Through trials, we have shown that our solution, the Whizz, helped patients overcome these hurdles, leading directly to reduced symptoms and better quality of life. Meracle was founded by a team with deep and complimentary experience in the medical device sector. Driven by our personal experience of family diagnosed with asthma, we understand the frustration of frequent exacerbation and emergency room visits despite regular follow-ups and increasing medication dosage. Thus, the inspiration emerged to bring this innovation to patients.